By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Fluidigm has paid Life Technologies $2 million to shield itself from litigation related to Life Tech's PCR patents, some of which were the subject of lawsuits the two firms filed against each other in June.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.